Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 96

1.

Providing both autologous and allogeneic hematopoietic stem cell transplants (HSCT) may have a stronger impact on the outcome of autologous HSCT in adult patients than activity levels or implementation of JACIE at Belgian transplant centres.

Poirel HA, Vanspauwen M, Macq G, De Geyndt A, Maertens J, Willems E, Selleslag D, Poiré X, Theunissen K, Graux C, Kerre T, Zachée P, Meuleman N, De Becker A, Verlinden A, Van Obbergh F, Schuermans C, De Wilde V, Jaspers A, Pranger D, Deeren D, Van Riet I, Vaes E, Beguin Y; Belgian Transplant Registry and the Belgian Haematological Society’s Transplant committee.

Bone Marrow Transplant. 2019 Sep;54(9):1434-1442. doi: 10.1038/s41409-019-0458-8. Epub 2019 Jan 29.

PMID:
30696999
2.

Mesenchymal stem cells in multiple myeloma: a therapeutical tool or target?

Xu S, De Veirman K, De Becker A, Vanderkerken K, Van Riet I.

Leukemia. 2018 Jul;32(7):1500-1514. doi: 10.1038/s41375-018-0061-9. Epub 2018 Feb 22. Review.

3.

Induction of miR-146a by multiple myeloma cells in mesenchymal stromal cells stimulates their pro-tumoral activity.

De Veirman K, Wang J, Xu S, Leleu X, Himpe E, Maes K, De Bruyne E, Van Valckenborgh E, Vanderkerken K, Menu E, Van Riet I.

Cancer Lett. 2016 Jul 10;377(1):17-24. doi: 10.1016/j.canlet.2016.04.024. Epub 2016 Apr 19.

PMID:
27102001
4.

Accessory cells for β-cell transplantation.

Staels W, De Groef S, Heremans Y, Coppens V, Van Gassen N, Leuckx G, Van de Casteele M, Van Riet I, Luttun A, Heimberg H, De Leu N.

Diabetes Obes Metab. 2016 Feb;18(2):115-24. doi: 10.1111/dom.12556. Epub 2015 Oct 9. Review.

PMID:
26289770
5.

Mesenchymal Stromal Cell Therapy in Hematology: From Laboratory to Clinic and Back Again.

De Becker A, Van Riet I.

Stem Cells Dev. 2015 Aug 1;24(15):1713-29. doi: 10.1089/scd.2014.0564. Epub 2015 Jun 4. Review.

PMID:
25923433
6.

Multiple myeloma induces Mcl-1 expression and survival of myeloid-derived suppressor cells.

De Veirman K, Van Ginderachter JA, Lub S, De Beule N, Thielemans K, Bautmans I, Oyajobi BO, De Bruyne E, Menu E, Lemaire M, Van Riet I, Vanderkerken K, Van Valckenborgh E.

Oncotarget. 2015 Apr 30;6(12):10532-47.

7.

Access to human tissues for research and product development: From EU regulation to alarming legal developments in Belgium.

Pirnay JP, Baudoux E, Cornu O, Delforge A, Delloye C, Guns J, Heinen E, Van den Abbeel E, Vanderkelen A, Van Geyt C, van Riet I, Verbeken G, De Sutter P, Verlinden M, Huys I, Cockbain J, Chabannon C, Dierickx K, Schotsmans P, De Vos D, Rose T, Jennes S, Sterckx S.

EMBO Rep. 2015 May;16(5):557-62. doi: 10.15252/embr.201540070. Epub 2015 Apr 7. No abstract available.

8.

Myeloid-derived suppressor cells as therapeutic target in hematological malignancies.

De Veirman K, Van Valckenborgh E, Lahmar Q, Geeraerts X, De Bruyne E, Menu E, Van Riet I, Vanderkerken K, Van Ginderachter JA.

Front Oncol. 2014 Dec 8;4:349. doi: 10.3389/fonc.2014.00349. eCollection 2014. Review.

9.

Cancer associated fibroblasts and tumor growth: focus on multiple myeloma.

De Veirman K, Rao L, De Bruyne E, Menu E, Van Valckenborgh E, Van Riet I, Frassanito MA, Di Marzo L, Vacca A, Vanderkerken K.

Cancers (Basel). 2014 Jun 27;6(3):1363-81. doi: 10.3390/cancers6031363.

10.

Upregulation of miR-135b is involved in the impaired osteogenic differentiation of mesenchymal stem cells derived from multiple myeloma patients.

Xu S, Cecilia Santini G, De Veirman K, Vande Broek I, Leleu X, De Becker A, Van Camp B, Vanderkerken K, Van Riet I.

PLoS One. 2013 Nov 6;8(11):e79752. doi: 10.1371/journal.pone.0079752. eCollection 2013.

11.

Epigenetic modulating agents as a new therapeutic approach in multiple myeloma.

Maes K, Menu E, Van Valckenborgh E, Van Riet I, Vanderkerken K, De Bruyne E.

Cancers (Basel). 2013 Apr 15;5(2):430-61. doi: 10.3390/cancers5020430.

12.

Vorinostat-induced bone loss might be related to drug toxicity.

Xu S, De Veirman K, Vanderkerken K, Van Riet I.

Bone. 2013 Dec;57(2):384-5. doi: 10.1016/j.bone.2013.08.024. Epub 2013 Aug 30. No abstract available.

PMID:
23999199
13.

A phase IB study on intravenous synthetic mRNA electroporated dendritic cell immunotherapy in pretreated advanced melanoma patients.

Wilgenhof S, Van Nuffel AM, Benteyn D, Corthals J, Aerts C, Heirman C, Van Riet I, Bonehill A, Thielemans K, Neyns B.

Ann Oncol. 2013 Oct;24(10):2686-93. doi: 10.1093/annonc/mdt245. Epub 2013 Jul 31.

PMID:
23904461
14.

Effect of the HDAC inhibitor vorinostat on the osteogenic differentiation of mesenchymal stem cells in vitro and bone formation in vivo.

Xu S, De Veirman K, Evans H, Santini GC, Vande Broek I, Leleu X, De Becker A, Van Camp B, Croucher P, Vanderkerken K, Van Riet I.

Acta Pharmacol Sin. 2013 May;34(5):699-709. doi: 10.1038/aps.2012.182. Epub 2013 Apr 8.

15.

In vitro expanded bone marrow-derived murine (C57Bl/KaLwRij) mesenchymal stem cells can acquire CD34 expression and induce sarcoma formation in vivo.

Xu S, De Becker A, De Raeve H, Van Camp B, Vanderkerken K, Van Riet I.

Biochem Biophys Res Commun. 2012 Aug 3;424(3):391-7. doi: 10.1016/j.bbrc.2012.06.118. Epub 2012 Jul 6.

PMID:
22771324
16.

Impaired osteogenic differentiation of mesenchymal stem cells derived from multiple myeloma patients is associated with a blockade in the deactivation of the Notch signaling pathway.

Xu S, Evans H, Buckle C, De Veirman K, Hu J, Xu D, Menu E, De Becker A, Vande Broek I, Leleu X, Camp BV, Croucher P, Vanderkerken K, Van Riet I.

Leukemia. 2012 Dec;26(12):2546-9. doi: 10.1038/leu.2012.126. Epub 2012 May 8. No abstract available.

PMID:
22652628
17.

Bone marrow-derived mesenchymal stromal cells are attracted by multiple myeloma cell-produced chemokine CCL25 and favor myeloma cell growth in vitro and in vivo.

Xu S, Menu E, De Becker A, Van Camp B, Vanderkerken K, Van Riet I.

Stem Cells. 2012 Feb;30(2):266-79. doi: 10.1002/stem.787.

18.

Quality controls of cryopreserved haematopoietic progenitor cells (peripheral blood, cord blood, bone marrow).

Rosskopf K, Ragg SJ, Worel N, Grommé M, Preijers FW, Braakman E, Schuurhuis GJ, van Riet I, Wendel S, Fontão-Wendel R, Lazar A, Goldman M, Halpenny M, Giulivi A, Letcher B, McGann L, Korhonen M, Arvola A, Humpe A, Buwitt-Beckmann U, Wiesneth M, Schauwecker P, Schrezenmeier H, Bönig H, Henschler R, Seifried E, Accorsi P, Bonfini T, Takanashi M, van Beckhoven JM, Brand A, Gounder D, Wong A, Dooccey R, Forrest E, Galea G, Smythe J, Pawson R, Reems JA, Oh J, Reesink HW, Panzer S.

Vox Sang. 2011 Oct;101(3):255-75. doi: 10.1111/j.1423-0410.2011.01471.x. No abstract available.

PMID:
21923889
19.

Therapeutic vaccination with an autologous mRNA electroporated dendritic cell vaccine in patients with advanced melanoma.

Wilgenhof S, Van Nuffel AM, Corthals J, Heirman C, Tuyaerts S, Benteyn D, De Coninck A, Van Riet I, Verfaillie G, Vandeloo J, Bonehill A, Thielemans K, Neyns B.

J Immunother. 2011 Jun;34(5):448-56. doi: 10.1097/CJI.0b013e31821dcb31.

PMID:
21577140
20.

Restoration of tumor equilibrium after immunotherapy for advanced melanoma: three illustrative cases.

Wilgenhof S, Pierret L, Corthals J, Van Nuffel AM, Heirman C, Roelandt T, De Coninck A, Verfaillie G, Vandenbroucke F, Van Riet I, Bonehill A, Thielemans K, Neyns B.

Melanoma Res. 2011 Apr;21(2):152-9. doi: 10.1097/CMR.0b013e328343ece0.

PMID:
21317818
21.

An improved harvest and in vitro expansion protocol for murine bone marrow-derived mesenchymal stem cells.

Xu S, De Becker A, Van Camp B, Vanderkerken K, Van Riet I.

J Biomed Biotechnol. 2010;2010:105940. doi: 10.1155/2010/105940. Epub 2010 Dec 20.

22.

Mouse spermatogonial stem cells obtain morphologic and functional characteristics of hematopoietic cells in vivo.

Ning L, Goossens E, Geens M, Van Saen D, Van Riet I, He D, Tournaye H.

Hum Reprod. 2010 Dec;25(12):3101-9. doi: 10.1093/humrep/deq269. Epub 2010 Oct 11.

PMID:
20940138
23.

Efficient differentiation of human embryonic stem cells into a homogeneous population of osteoprogenitor-like cells.

Mateizel I, De Becker A, Van de Velde H, De Rycke M, Van Steirteghem A, Cornelissen R, Van der Elst J, Liebaers I, Van Riet I, Sermon K.

Reprod Biomed Online. 2008 May;16(5):741-53.

PMID:
18492382
24.

Epigenetic silencing of the tetraspanin CD9 during disease progression in multiple myeloma cells and correlation with survival.

De Bruyne E, Bos TJ, Asosingh K, Vande Broek I, Menu E, Van Valckenborgh E, Atadja P, Coiteux V, Leleu X, Thielemans K, Van Camp B, Vanderkerken K, Van Riet I.

Clin Cancer Res. 2008 May 15;14(10):2918-26. doi: 10.1158/1078-0432.CCR-07-4489.

25.

Evaluation of 'out-of-specification' CliniMACS CD34-selection procedures of hematopoietic progenitor cell-apheresis products.

Braakman E, Schuurhuis GJ, Preijers FW, Voermans C, Theunissen K, van Riet I, Fibbe WE, Slaper-Cortenbach I.

Cytotherapy. 2008;10(1):83-9. doi: 10.1080/14653240701787650.

PMID:
18202977
26.

Extravasation and homing mechanisms in multiple myeloma.

Vande Broek I, Vanderkerken K, Van Camp B, Van Riet I.

Clin Exp Metastasis. 2008;25(4):325-34. Epub 2007 Oct 19. Review.

PMID:
17952614
27.

Evidence that intracoronary-injected CD133+ peripheral blood progenitor cells home to the myocardium in chronic postinfarction heart failure.

Schots R, De Keulenaer G, Schoors D, Caveliers V, Dujardin M, Verheye S, Van Camp G, Franken PR, Roland J, Van Riet I, Everaert H.

Exp Hematol. 2007 Dec;35(12):1884-90. Epub 2007 Oct 17.

PMID:
17923244
28.

Migration of culture-expanded human mesenchymal stem cells through bone marrow endothelium is regulated by matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-3.

De Becker A, Van Hummelen P, Bakkus M, Vande Broek I, De Wever J, De Waele M, Van Riet I.

Haematologica. 2007 Apr;92(4):440-9.

29.

Chromatin remodeling agent trichostatin A: a key-factor in the hepatic differentiation of human mesenchymal stem cells derived of adult bone marrow.

Snykers S, Vanhaecke T, De Becker A, Papeleu P, Vinken M, Van Riet I, Rogiers V.

BMC Dev Biol. 2007 Apr 2;7:24.

30.

Neighboring adipocytes participate in the bone marrow microenvironment of multiple myeloma cells.

Caers J, Deleu S, Belaid Z, De Raeve H, Van Valckenborgh E, De Bruyne E, Defresne MP, Van Riet I, Van Camp B, Vanderkerken K.

Leukemia. 2007 Jul;21(7):1580-4. Epub 2007 Mar 22. No abstract available.

31.

In vivo visualization of 111In labeled CD133+ peripheral blood stem cells after intracoronary administration in patients with chronic ischemic heart disease.

Caveliers V, De Keulenaer G, Everaert H, Van Riet I, Van Camp G, Verheye S, Roland J, Schoors D, Franken PR, Schots R.

Q J Nucl Med Mol Imaging. 2007 Mar;51(1):61-6.

32.

Role of CCR1 and CCR5 in homing and growth of multiple myeloma and in the development of osteolytic lesions: a study in the 5TMM model.

Menu E, De Leenheer E, De Raeve H, Coulton L, Imanishi T, Miyashita K, Van Valckenborgh E, Van Riet I, Van Camp B, Horuk R, Croucher P, Vanderkerken K.

Clin Exp Metastasis. 2006;23(5-6):291-300. Epub 2006 Nov 3.

PMID:
17086356
33.

Endothelial cell-driven regulation of CD9 or motility-related protein-1 expression in multiple myeloma cells within the murine 5T33MM model and myeloma patients.

De Bruyne E, Andersen TL, De Raeve H, Van Valckenborgh E, Caers J, Van Camp B, Delaissé JM, Van Riet I, Vanderkerken K.

Leukemia. 2006 Oct;20(10):1870-9. Epub 2006 Aug 10.

34.

The involvement of stromal derived factor 1alpha in homing and progression of multiple myeloma in the 5TMM model.

Menu E, Asosingh K, Indraccolo S, De Raeve H, Van Riet I, Van Valckenborgh E, Vande Broek I, Fujii N, Tamamura H, Van Camp B, Vanderkerken K.

Haematologica. 2006 May;91(5):605-12. Epub 2006 Apr 19. Erratum in: Haematologica. 2007 Nov;92(11):1584. Van de Broek, Isabelle [corrected to Vande Broek, Isabelle].

35.

Clinical significance of chemokine receptor (CCR1, CCR2 and CXCR4) expression in human myeloma cells: the association with disease activity and survival.

Vande Broek I, Leleu X, Schots R, Facon T, Vanderkerken K, Van Camp B, Van Riet I.

Haematologica. 2006 Feb;91(2):200-6. Erratum in: Haematologica. 2007 Nov;92(11):1584. Van de Broek, Isabelle [corrected to Vande Broek, Isabelle].

36.

The involvement of osteopontin and its receptors in multiple myeloma cell survival, migration and invasion in the murine 5T33MM model.

Caers J, Günthert U, De Raeve H, Van Valckenborgh E, Menu E, Van Riet I, Van Camp B, Vanderkerken K.

Br J Haematol. 2006 Feb;132(4):469-77.

PMID:
16412019
37.

Mesenchymal stem cell adhesion to cardiac microvascular endothelium: activators and mechanisms.

Segers VF, Van Riet I, Andries LJ, Lemmens K, Demolder MJ, De Becker AJ, Kockx MM, De Keulenaer GW.

Am J Physiol Heart Circ Physiol. 2006 Apr;290(4):H1370-7. Epub 2005 Oct 21.

38.

Targeting an MMP-9-activated prodrug to multiple myeloma-diseased bone marrow: a proof of principle in the 5T33MM mouse model.

Van Valckenborgh E, Mincher D, Di Salvo A, Van Riet I, Young L, Van Camp B, Vanderkerken K.

Leukemia. 2005 Sep;19(9):1628-33.

PMID:
16015389
39.

Role of the hypoxic bone marrow microenvironment in 5T2MM murine myeloma tumor progression.

Asosingh K, De Raeve H, de Ridder M, Storme GA, Willems A, Van Riet I, Van Camp B, Vanderkerken K.

Haematologica. 2005 Jun;90(6):810-7.

40.

Multifunctional role of matrix metalloproteinases in multiple myeloma: a study in the 5T2MM mouse model.

Van Valckenborgh E, Croucher PI, De Raeve H, Carron C, De Leenheer E, Blacher S, Devy L, Noël A, De Bruyne E, Asosingh K, Van Riet I, Van Camp B, Vanderkerken K.

Am J Pathol. 2004 Sep;165(3):869-78.

41.

Myeloma cells (5TMM) and their interactions with the marrow microenvironment.

Menu E, Asosingh K, Van Riet I, Croucher P, Van Camp B, Vanderkerken K.

Blood Cells Mol Dis. 2004 Sep-Oct;33(2):111-9. Review.

PMID:
15315788
42.

Angiogenic switch during 5T2MM murine myeloma tumorigenesis: role of CD45 heterogeneity.

Asosingh K, De Raeve H, Menu E, Van Riet I, Van Marck E, Van Camp B, Vanderkerken K.

Blood. 2004 Apr 15;103(8):3131-7. Epub 2003 Nov 26.

PMID:
15070695
43.

Bone marrow endothelial cells increase the invasiveness of human multiple myeloma cells through upregulation of MMP-9: evidence for a role of hepatocyte growth factor.

Vande Broek I, Asosingh K, Allegaert V, Leleu X, Facon T, Vanderkerken K, Van Camp B, Van Riet I.

Leukemia. 2004 May;18(5):976-82.

PMID:
14999296
44.

Growth factor receptor profile of CD34 cells in normal bone marrow, cord blood and mobilized peripheral blood.

De Waele M, Renmans W, Asosingh K, Vander Gucht K, Van Riet I.

Eur J Haematol. 2004 Mar;72(3):193-202.

PMID:
14962238
45.

Delayed in vivo disease progression is associated with high proportions of CD45+ myeloma cells in the 5T2MM murine model.

Asosingh K, Willems A, Van Riet I, Van Camp B, Vanderkerken K.

Cancer Res. 2003 Jun 15;63(12):3019-20.

46.

Proinflammatory cytokines and their role in the development of major transplant-related complications in the early phase after allogeneic bone marrow transplantation.

Schots R, Kaufman L, Van Riet I, Ben Othman T, De Waele M, Van Camp B, Demanet C.

Leukemia. 2003 Jun;17(6):1150-6.

PMID:
12764383
47.
48.
49.

Mechanisms involved in the differential bone marrow homing of CD45 subsets in 5T murine models of myeloma.

Asosingh K, Menu E, Van Valckenborgh E, Vande Broek I, Van Riet I, Van Camp B, Vanderkerken K.

Clin Exp Metastasis. 2002;19(7):583-91.

PMID:
12498387
50.

The F-actin content of multiple myeloma cells as a measure of their migration.

Menu E, Braet F, Timmers M, Van Riet I, Van Camp B, Vanderkerken K.

Ann N Y Acad Sci. 2002 Nov;973:124-36.

PMID:
12485848

Supplemental Content

Loading ...
Support Center